Skip Nav Destination
Issues
1 October 2017
-
Cover Image
Cover Image
The cover shows a section of a pediatric patient-derived group 3 medulloblastoma tumor that regressed following treatment with a CDK4/6 inhibitor called palbociclib (Ibrance, Pfizer, Inc.). Histologic analysis revealed that the drug caused a significant change in the morphology of the tumor cells, including cytomegaly, vacuolated chromatin, and prominent nucleoli. For details, see the article by Cook Sangar and colleagues on page 5802 of this issue. - PDF Icon PDF LinkTable of Contents
- PDF Icon PDF LinkEditorial Board
ISSN 1078-0432
EISSN 1557-3265
Highlights
CCR Drug Updates
FDA Approval Summary: Pembrolizumab for the Treatment of Patients with Unresectable or Metastatic Melanoma
Amy Barone; Maitreyee Hazarika; Marc R. Theoret; Pallavi Mishra-Kalyani; Huanyu Chen; Kun He; Rajeshwari Sridhara; Sriram Subramaniam; Elimika Pfuma; Yaning Wang; Hongshan Li; Hong Zhao; Jeanne Fourie Zirkelbach; Patricia Keegan; Richard Pazdur
FDA Approval Summary: Accelerated Approval of Pembrolizumab for Second-Line Treatment of Metastatic Melanoma
Meredith K. Chuk; Jennie T. Chang; Marc R. Theoret; Emmanuel Sampene; Kun He; Shawna L. Weis; Whitney S. Helms; Runyan Jin; Hongshan Li; Jingyu Yu; Hong Zhao; Liang Zhao; Mark Paciga; Deborah Schmiel; Rashmi Rawat; Patricia Keegan; Richard Pazdur
Cancer Therapy: Clinical
Efficacy of Sequential Ipilimumab Monotherapy versus Best Supportive Care for Unresectable Locally Advanced/Metastatic Gastric or Gastroesophageal Junction Cancer
Yung-Jue Bang; Jae Yong Cho; Yeul Hong Kim; Jin Won Kim; Maria Di Bartolomeo; Jaffer A. Ajani; Kensei Yamaguchi; Agnes Balogh; Teresa Sanchez; Markus Moehler
Local Adjuvant Treatment with Low-Dose CpG-B Offers Durable Protection against Disease Recurrence in Clinical Stage I–II Melanoma: Data from Two Randomized Phase II Trials
Bas D. Koster; Mari F.C.M. van den Hout; Berbel J.R. Sluijter; Barbara G. Molenkamp; Ronald J.C.L.M. Vuylsteke; Arnold Baars; Paul A.M. van Leeuwen; Rik J. Scheper; M. Petrousjka van den Tol; Alfons J.M. van den Eertwegh; Tanja D. de Gruijl
Neratinib Efficacy and Circulating Tumor DNA Detection of HER2 Mutations in HER2 Nonamplified Metastatic Breast Cancer
Cynthia X. Ma; Ron Bose; Feng Gao; Rachel A. Freedman; Melinda L. Telli; Gretchen Kimmick; Eric Winer; Michael Naughton; Matthew P. Goetz; Christy Russell; Debu Tripathy; Melody Cobleigh; Andres Forero; Timothy J. Pluard; Carey Anders; Polly Ann Niravath; Shana Thomas; Jill Anderson; Caroline Bumb; Kimberly C. Banks; Richard B. Lanman; Richard Bryce; Alshad S. Lalani; John Pfeifer; Daniel F. Hayes; Mark Pegram; Kimberly Blackwell; Philippe L. Bedard; Hussam Al-Kateb; Matthew J.C. Ellis
Phase I Trial of Intravenous Oncolytic Vaccinia Virus (GL-ONC1) with Cisplatin and Radiotherapy in Patients with Locoregionally Advanced Head and Neck Carcinoma
Loren K. Mell; Kevin T. Brumund; Gregory A. Daniels; Sunil J. Advani; Kaveh Zakeri; Mary E. Wright; Sara-Jane Onyeama; Robert A. Weisman; Parag R. Sanghvi; Peter J. Martin; Aladar A. Szalay
Author Choice
First-in-Human Study of AMG 820, a Monoclonal Anti-Colony-Stimulating Factor 1 Receptor Antibody, in Patients with Advanced Solid Tumors
Kyriakos P. Papadopoulos; Larry Gluck; Lainie P. Martin; Anthony J. Olszanski; Anthony W. Tolcher; Gataree Ngarmchamnanrith; Erik Rasmussen; Benny M. Amore; Dirk Nagorsen; John S. Hill; Joe Stephenson, Jr
Therapy of Small Cell Lung Cancer (SCLC) with a Topoisomerase-I–inhibiting Antibody–Drug Conjugate (ADC) Targeting Trop-2, Sacituzumab Govitecan
Jhanelle E. Gray; Rebecca S. Heist; Alexander N. Starodub; D. Ross Camidge; Ebenezer A. Kio; Gregory A. Masters; W. Thomas Purcell; Michael J. Guarino; Jamal Misleh; Charles J. Schneider; Bryan J. Schneider; Allyson Ocean; Tirrell Johnson; Leena Gandhi; Kevin Kalinsky; Ronald Scheff; Wells A. Messersmith; Serengulam V. Govindan; Pius P. Maliakal; Boyd Mudenda; William A. Wegener; Robert M. Sharkey; David M. Goldenberg
Personalized Medicine and Imaging
Diffusion MRI Phenotypes Predict Overall Survival Benefit from Anti-VEGF Monotherapy in Recurrent Glioblastoma: Converging Evidence from Phase II Trials
Benjamin M. Ellingson; Elizabeth R. Gerstner; Marion Smits; Raymond Y. Huang; Rivka Colen; Lauren E. Abrey; Dana T. Aftab; Gisela M. Schwab; Colin Hessel; Robert J. Harris; Ararat Chakhoyan; Renske Gahrmann; Whitney B. Pope; Kevin Leu; Catalina Raymond; Davis C. Woodworth; John de Groot; Patrick Y. Wen; Tracy T. Batchelor; Martin J. van den Bent; Timothy F. Cloughesy
Clinical and Genome-Wide Analysis of Cisplatin-Induced Peripheral Neuropathy in Survivors of Adult-Onset Cancer
M. Eileen Dolan; for the Platinum Study Group; Omar El Charif; for the Platinum Study Group; Heather E. Wheeler; for the Platinum Study Group; Eric R. Gamazon; for the Platinum Study Group; Shirin Ardeshir-Rouhani-Fard; for the Platinum Study Group; Patrick Monahan; for the Platinum Study Group; Darren R. Feldman; for the Platinum Study Group; Robert J. Hamilton; for the Platinum Study Group; David J. Vaughn; for the Platinum Study Group; Clair J. Beard; for the Platinum Study Group; Chunkit Fung; for the Platinum Study Group; Jeri Kim; for the Platinum Study Group; Sophie D. Fossa; for the Platinum Study Group; Daniel L Hertz; for the Platinum Study Group; Taisei Mushiroda; for the Platinum Study Group; Michiaki Kubo; for the Platinum Study Group; Lawrence H. Einhorn; for the Platinum Study Group; Nancy J. Cox; for the Platinum Study Group; Lois B. Travis; for the Platinum Study Group
PD-1+ Polyfunctional T Cells Dominate the Periphery after Tumor-Infiltrating Lymphocyte Therapy for Cancer
Marco Donia; Julie Westerlin Kjeldsen; Rikke Andersen; Marie Christine Wulff Westergaard; Valentina Bianchi; Mateusz Legut; Meriem Attaf; Barbara Szomolay; Sascha Ott; Garry Dolton; Rikke Lyngaa; Sine Reker Hadrup; Andrew K. Sewell; Inge Marie Svane
Cancer Therapy: Preclinical
Combined BTK and PI3Kδ Inhibition with Acalabrutinib and ACP-319 Improves Survival and Tumor Control in CLL Mouse Model
Carsten U. Niemann; Helena I. Mora-Jensen; Eman L. Dadashian; Fanny Krantz; Todd Covey; Shih-Shih Chen; Nicholas Chiorazzi; Raquel Izumi; Roger Ulrich; Brian J. Lannutti; Adrian Wiestner; Sarah E.M. Herman
SYD985, a Novel Duocarmycin-Based HER2-Targeting Antibody–Drug Conjugate, Shows Antitumor Activity in Uterine and Ovarian Carcinosarcoma with HER2/Neu Expression
Gulden Menderes; Elena Bonazzoli; Stefania Bellone; Jonathan Black; Federica Predolini; Francesca Pettinella; Alice Masserdotti; Luca Zammataro; Gary Altwerger; Natalia Buza; Pei Hui; Serena Wong; Babak Litkouhi; Elena Ratner; Dan-Arin Silasi; Masoud Azodi; Peter E. Schwartz; Alessandro D. Santin
Fractionated Dosing Improves Preclinical Therapeutic Index of Pyrrolobenzodiazepine-Containing Antibody Drug Conjugates
Mary Jane Masson Hinrichs; Pauline M. Ryan; Bo Zheng; Shameen Afif-Rider; Xiang Qing Yu; Michele Gunsior; Haihong Zhong; Jay Harper; Binyam Bezabeh; Kapil Vashisht; Marlon Rebelatto; Molly Reed; Patricia C. Ryan; Shannon Breen; Neki Patel; Cui Chen; Luke Masterson; Arnaud Tiberghien; Phillip W. Howard; Nazzareno Dimasi; Rakesh Dixit
Author Choice
Combination Therapy with NHS-muIL12 and Avelumab (anti-PD-L1) Enhances Antitumor Efficacy in Preclinical Cancer Models
Chunxiao Xu; Yanping Zhang; P. Alexander Rolfe; Vivian M. Hernández; Wilson Guzman; Giorgio Kradjian; Bo Marelli; Guozhong Qin; Jin Qi; Hong Wang; Huakui Yu; Robert Tighe; Kin-Ming Lo; Jessie M. English; Laszlo Radvanyi; Yan Lan
MUC1-Mediated Metabolic Alterations Regulate Response to Radiotherapy in Pancreatic Cancer
Venugopal Gunda; Joshua Souchek; Jaime Abrego; Surendra K. Shukla; Gennifer D. Goode; Enza Vernucci; Aneesha Dasgupta; Nina V. Chaika; Ryan J. King; Sicong Li; Shuo Wang; Fang Yu; Tadayoshi Bessho; Chi Lin; Pankaj K. Singh
Downregulation of Human Endogenous Retrovirus Type K (HERV-K) Viral env RNA in Pancreatic Cancer Cells Decreases Cell Proliferation and Tumor Growth
Ming Li; Laszlo Radvanyi; Bingnan Yin; Kiera Rycaj; Jia Li; Raghavender Chivukula; Kevin Lin; Yue Lu; JianJun Shen; David Z. Chang; Donghui Li; Gary L. Johanning; Feng Wang-Johanning
Elevation of TP53 Autoantibody Before CA125 in Preclinical Invasive Epithelial Ovarian Cancer
Wei-Lei Yang; Aleksandra Gentry-Maharaj; Archana Simmons; Andy Ryan; Evangelia Ourania Fourkala; Zhen Lu; Keith A. Baggerly; Yang Zhao; Karen H. Lu; David Bowtell; for the AOCS Study Group; Ian Jacobs; Steven J. Skates; Wei-Wu He; Usha Menon; Robert C. Bast, Jr
Sym015: A Highly Efficacious Antibody Mixture against MET-Amplified Tumors
Thomas Tuxen Poulsen; Michael Monrad Grandal; Niels Jørgen Østergaard Skartved; Rikke Hald; Lene Alifrangis; Klaus Koefoed; Trine Lindsted; Camilla Fröhlich; Sofie Ellebæk Pollmann; Karsten Wessel Eriksen; Anna Dahlman; Helle Jane Jacobsen; Thomas Bouquin; Mikkel Wandahl Pedersen; Ivan David Horak; Johan Lantto; Michael Kragh
Biology of Human Tumors
Mutational Heterogeneity in APC and KRAS Arises at the Crypt Level and Leads to Polyclonality in Early Colorectal Tumorigenesis
Mireia Gausachs; Ester Borras; Kyle Chang; Sara Gonzalez; Daniel Azuara; Axel Delgado Amador; Adriana Lopez-Doriga; F. Anthony San Lucas; Xavier Sanjuan; Maria J. Paules; Melissa W. Taggart; Gareth E. Davies; Erik A. Ehli; Jerry Fowler; Victor Moreno; Marta Pineda; Y. Nancy You; Patrick M. Lynch; Conxi Lazaro; Nicholas E. Navin; Paul A. Scheet; Ernest T. Hawk; Gabriel Capella; Eduardo Vilar
Author Choice
Sequential Tracking of PD-L1 Expression and RAD50 Induction in Circulating Tumor and Stromal Cells of Lung Cancer Patients Undergoing Radiotherapy
Daniel L. Adams; Diane K. Adams; Jianzhong He; Neda Kalhor; Ming Zhang; Ting Xu; Hui Gao; James M. Reuben; Yawei Qiao; Ritsuko Komaki; Zhongxing Liao; Martin J. Edelman; Cha-Mei Tang; Steven H. Lin
Use of Angiotensin System Inhibitors Is Associated with Immune Activation and Longer Survival in Nonmetastatic Pancreatic Ductal Adenocarcinoma
Hao Liu; Kamila Naxerova; Matthias Pinter; Joao Incio; Hang Lee; Kohei Shigeta; William W. Ho; Jonathan A. Crain; Alex Jacobson; Theodoros Michelakos; Daniella Dias-Santos; Andrea Zanconato; Theodore S. Hong; Jeffrey W. Clark; Janet E. Murphy; David P. Ryan; Vikram Deshpande; Keith D. Lillemoe; Carlos Fernandez-del Castillo; Michael Downes; Ronald M. Evans; James Michaelson; Cristina R. Ferrone; Yves Boucher; Rakesh K. Jain
Genomic Alterations in Fatal Forms of Non-Anaplastic Thyroid Cancer: Identification of MED12 and RBM10 as Novel Thyroid Cancer Genes Associated with Tumor Virulence
Tihana Ibrahimpasic; Bin Xu; Iñigo Landa; Snjezana Dogan; Sumit Middha; Venkatraman Seshan; Shyam Deraje; Diane L. Carlson; Jocelyn Migliacci; Jeffrey A. Knauf; Brian Untch; Michael F. Berger; Luc Morris; R. Michael Tuttle; Timothy Chan; James A. Fagin; Ronald Ghossein; Ian Ganly
Author Choice
A First-Time-in-Human Study of GSK2636771, a Phosphoinositide 3 Kinase Beta-Selective Inhibitor, in Patients with Advanced Solid Tumors
Joaquin Mateo; Gopinath Ganji; Charlotte Lemech; Howard A. Burris; Sae-Won Han; Karen Swales; Shaun Decordova; M. Phillip DeYoung; Deborah A. Smith; Shanker Kalyana-Sundaram; Jiuhua Wu; Monica Motwani; Rakesh Kumar; Jerry M. Tolson; Sun Young Rha; Hyun Cheol Chung; Joseph P. Eder; Sunil Sharma; Yung-Jue Bang; Jeffrey R. Infante; Li Yan; Johann S. de Bono; Hendrik-Tobias Arkenau
Letter to the Editor
Correction
Advertisement
Email alerts
NOTICE: This notice serves to inform the reader that, in 2023, AACR received a donation by Pfizer of the rights to royalties from the sale—within the United States—of Bavencio® (avelumab), a pharmaceutical owned by Merck. None of these funds are being, or will be, used to directly support any specific publication or author. If an individual article is published that deals with this particular drug, such article will include standard financial disclosures per AACR journal policy. For more detail regarding AACR’s established policies for authors, please go to https://aacrjournals.org/pages/editorial-policies#coi.
RSS Feeds